INKT vs INO

MiNK Therapeutics, Inc. vs Inovio Pharmaceuticals, Inc. — Valuation Comparison 2026

INKT

Biotechnology
MiNK Therapeutics, Inc.
Quality
4.0
out of 10
Value Trap
18
SAFE
Price
$12.20
Last close
Models
9/13
Active
VS

INO

Biotechnology
Inovio Pharmaceuticals, Inc.
Quality
4.3
out of 10
Value Trap
47
WARN
Price
$1.30
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType INKT Fair ValueINKT Upside INO Fair ValueINO Upside
Bayesian DCF Intrinsic $4.31 -64.7% $0.48 -63.1%
Earnings Power Value Intrinsic $3.25 -72.0%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $4.56 -62.6% $2.08 +60.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for INKT vs INO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INKT vs INO — Which Stock Is More Undervalued?

INO scores higher with a 4.3/10 quality rating vs INKT's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MiNK Therapeutics, Inc. (INKT) and Inovio Pharmaceuticals, Inc. (INO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INKT currently trades at $12.20 with a QOC of 4.0/10, while INO trades at $1.30 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).